Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Daniele Generali(University of Trieste), Giuseppina Barbieri(Istituti Ospitalieri di Cremona), Filippo Montemurro(Roche (Switzerland)), Valeria Cervoni(University of Trieste), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Marianna Sirico(Istituti Ospitalieri di Cremona), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Carla Strina(Istituti Ospitalieri di Cremona), Eva Ciruelos(Hospital Universitario 12 De Octubre), Martina Dester(Istituti Ospitalieri di Cremona), Ottavia Bernocchi(University of Trieste), Manuela Milani(Humanitas University), Fabiola Giudici(University of Padua)
Cited by 0
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684